The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ? Reilly R. Kayser, Ivar Snorrason, Margaret Haney, Francis S. Lee, and H. Blair Simpson1 Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0049 Abstract Introduction : Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments. Discussion : A growing body of basic and clinical research has showed that the endocannabinoid system(ECS) plays a role in [...]
Lire la suiteCannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. AJP in Advance, 2019, 1-12. doi: 10.1176/appi.ajp.2019.18101191 Objective : Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often [...]
Lire la suiteLa psychothérapie psychédélique est de retour M le magazine du Monde | 12.03.2015 Mescaline, ecstasy, psilocybine soigneront-ils la dépression, l’angoisse, l’autisme ou l’alcoolisme ? Des psychiatres américains explorent le potentiel thérapeutique de ces substances illicites. Par Stéphanie Chayet Engourdissement, d’abord. Puis grande fatigue, bâillements. Des images, très abstraites, comme de l’art moderne. Des motifs. Image d’un chat en train de mordiller le câble de freinage d’un vélo. Après ça ? Sentiment de ne pas m’aimer. Pas du tout. Puis je me demande : pourquoi je ne m’aimerais pas ? Il n’y a aucune raison. » Ainsi commence, mot pour mot, le « compte rendu d’expérience [...]
Lire la suiteCannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders Jonathan L.C. Lee, Leandro J. Bertoglio, Francisco S. Guimarães and Carl W. Stevenson British Journal of Pharmacology, 2017, 174, 3242–3256 DOI : 10.1111/bph.13724 Abstract Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotionalmemories and inadequate treatment, often leading to symptom relapse. [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an anxiolytic drug Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, Adriana Cardoso de Oliveira e Silva, Jaime Eduardo Cecilio Hallak, José Alexandre S. Crippa, Antonio E. Nardi, Antonio Waldo Zuardi Revista Brasileira de Psiquiatria, 2012, 34 (Supl1), S104-S117 1516-4446 - ©2012 Elsevier Editora Ltda. All rights reserved. Abstract Objectives : To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. Method : The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI [...]
Lire la suiteCannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479) Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041 ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]
Lire la suiteDoes cannabidiol protect against adverse psychological effects of THC ? Raymond J. M. Niesink and Margriet W. van Laar Frontiers in Psychiatry, 2013, 4, 130 doi : 10.3389/fpsyt.2013.00130. Abstract The recreational use of cannabis can have persistent adverse effects on mental health. Delta 9-tetrahydro-cannabinol (THC) is the main psychoactive constituent of cannabis, and most, if not all, of the effects associated with the use of cannabis are caused by THC. Recent studies have suggested a possible protective effect of another cannabinoid, cannabidiol (CBD). A literature search was performed in the bibliographic databases PubMed, PsycINFO, andWeb of Science using the keyword “cannabidiol.” After removing duplicate entries, [...]
Lire la suiteLong-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis Kitti Rusznák, Kata Csekö, Zsófia Varga, Dávid Csabai, Ágnes Bóna, Mátyás Mayer, Zsolt Kozma, Zsuzsanna Helyes and Boldizsár Czéh Frontiers in Pharmacology, 2018, 9, 786 doi: 10.3389/fphar.2018.00786. eCollection 2018 www.frontiersin.org Abstract Marijuana is a widely used recreational drug with increasing legalization worldwide for medical purposes. Most experimental studies use either synthetic or plant-derived cannabinoids to investigate the effect of cannabinoids on anxiety and cognitive functions. The aim of this study was to mimic real life situations where young people smoke cannabis regularly to relax from everyday stress. Therefore, we exposed young adult [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suite